The UK and US have secured a important commercial pact that will maintain zero tariffs on British pharmaceutical products being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has committed to increase expenditure on pharmaceuticals through the public health system. This commitment secures that duties on these key exports will be held at zero for a period of 36 months.
This development comes after earlier statements to significantly raise import taxes on branded pharmaceutical imports, with potential rates floated as high as double the cost.
"This agreement with the United Kingdom reinforces the global environment for cutting-edge drugs and brings much-needed balance to U.S.–U.K. pharmaceutical trade," a release declared.
Trade Importance
Drugs are one of the UK's most significant export categories to the America, which is by far the biggest destination for major UK drugmakers.
Export figures indicate that in the 12 months leading up to the third quarter, the UK exported medicines worth billions to the US. This figure accounted for a significant portion of British export trade in that span.
"This deal protects jobs, increases capital expenditure and facilitates the UK to become a international leader for biotech and pharma," a government official commented.
Specific UK Commitments
The deal entails several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a target to double overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must refund to the NHS to stay within budget will be capped at 15%. Previously, rebates exceeded 20%.
Recent Tensions
The pact follows a long-running dispute between the sector and the British authorities over medicine costs and regulatory access.
This friction were exacerbated by assertions that American customers were charged several times more for the same drugs than consumers in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or abandoned, while major investments have been directed toward American operations.
One official stated that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the last ten years.